Research programme: cancer therapeutics - sigma-tau

Drug Profile

Research programme: cancer therapeutics - sigma-tau

Alternative Names: DN-30; MvDN 30

Latest Information Update: 29 Feb 2016

Price : $50

At a glance

  • Originator sigma-tau SpA
  • Class Antibodies
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Feb 2016 DN 30 is available for licensing as of 29 Feb 2016. http://www.sigma-tau.it
  • 20 Aug 2010 Preclinical development is ongoing in Italy
  • 07 Nov 2006 Preclinical trials in Cancer in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top